Background: Psoriasis, a common chronic inflammatory disease, increases the risk of developing multiple sclerosis (MS), but evidence for this outcome is still unclear. However, we performed a meta-analysis of relevant studies to quantify the magnitude of the association between psoriasis and MS. It will help to assess the current state of knowledge, fill the gaps in our existing concern, and make a recommendation for future research. Methods: PubMed, EMBASE, and the bibliographies of articles were searched for studies published between January 1, 1990, and November 1, 2017, which reported on the association between psoriasis and MS. Articles were included if they (1) were published in English, (2) reported patients with psoriasis, and the outcome of interest was MS, (3) provided OR/RR/HR with 95% CI or sufficient information to calculate the 95% CI, and (4) if ≥50 patients. All abstracts, full-text articles, and sources were reviewed, with duplicate data excluded. Summary relative risk (ORs) with 95% CI was pooled using a random-effects model. Subgroup and sensitivity analyses were also conducted. Results: We selected 11 articles out of 785 unique abstracts for full-text review using our predetermined selection criteria, and 9 out of these 11 studies met all of our inclusion criteria. The overall pooled increased of developing MS in patients with psoriasis was RR 1.607 (95% CI 1.322–1.953, p < 0.0001) with low heterogeneity (I2 = 37.41%, Q = 12.782, τ2 = 0.027) for the random effect model. In the subgroup analysis, the MS risk in the patient with psoriasis was also significantly higher in the 6 studies from Europe RR 1.57 (95% CI 1.26–1.94, p < 0.001) with moderate heterogeneity (I2 = 50.66%, Q = 10.13, τ2 = 0.03) for the random effect model. Conclusion: Our results showed that psoriasis is significantly associated with an increased risk of developing MS. Physicians should carefully be observed symptoms and empower their patients to improve existing knowledge and quality of life. Further studies are warranted to establish the mechanisms underlying this relationship.

Keywords:
Psoriasis, Inflammatory disorder, Multiple sclerosis, Meta-analysis, Autoimmune disease
1.
Naldi L: Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3: 121–128.
2.
Danielsen K, Olsen AO, Wilsgaard T, Furberg AS: Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol 2013; 168: 1303–1310.
3.
Arthur M: Institute for Health Metrics and Evaluation, RCN Publishing Company Limited, 2014.
4.
Wootla B, Eriguchi M, Rodriguez M: Is multiple sclerosis an autoimmune disease? Autoimmune Dis 2012; 2012: 969657.
5.
Frohman EM, Racke MK, Raine CS: Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med 2006; 354: 942–955.
6.
International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2: Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214–219.
7.
Wu GF, Alvarez E: The immunopathophysiology of multiple sclerosis. Neurol Clin 2011; 29: 257–278.
8.
Dobson R, Giovannoni G: Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis. J Neurol 2013; 260: 1272–1285.
9.
Lovett-Racke AE, Yang Y, Racke MK: Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta 2011; 1812: 246–251.
10.
Damsker JM, Hansen AM, Caspi RR: Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci 2010; 1183: 211–221.
11.
Barcellos LF, Kamdar BB, Ramsay PP, DeLoa C, Lincoln RR, Caillier S, Schmidt S, Haines JL, Pericak-Vance MA, Oksenberg JR, Hauser SL: Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol 2006; 5: 924–931.
12.
Dong C: TH17 cells in development: an updated view of molecular identity and genetic programming. Nat Rev Immunol 2008; 8: 337–348.
13.
Poly TN, Islam MM, Walther BA, Yang HC, Nguyen PA, Huang CW, Shabbir SA, Li YJ: Exploring the association between statin use and the risk of Parkinson’s disease: a meta-analysis of observational studies. Neuroepidemiology 2017; 49: 142–151.
14.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557.
15.
Islam MM, Iqbal U, Walther B, Atique S, Dubey NK, Nguyen PA, Poly TN, Masud JH, Li YJ, Shabbir SA: Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology 2016; 47: 181–191.
16.
Islam MM, Yang HC, Nguyen PA, Poly TN, Huang CW, Kekade S, Khalfan AM, Debnath T, Li YJ, Abdul SS: Exploring association between statin use and breast cancer risk: an updated meta-analysis. Arch Gynecol Obstet 2017; 296: 1043–1053.
17.
Islam MM, Iqbal U, Walther BA, Nguyen PA, Li YJ, Dubey NK, Poly TN, Masud JHB, Atique S, Syed-Abdul S: Gender-based personalized pharmacotherapy: a systematic review. Arch Gynecol Obstet 2017; 295: 1305–1317.
18.
Yang HC, Nguyen PAA, Islam M, Huang CW, Poly TN, Iqbal U, Li YJ: Gout drugs use and risk of cancer: a case-control study. Joint Bone Spine 2018:pii:S1297-319X(18)30010-1.
19.
Egeberg A, Mallbris L, Gislason GH, Skov L, Hansen PR: Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study. J Invest Dermatol 2016; 136: 93–98.
20.
Fellner A, Dano M, Regev K, Mosek A, Karni A: Multiple sclerosis is associated with psoriasis. A case-control study. J Neurol Sci 2014; 338: 226–228.
21.
Ramagopalan SV, Dyment DA, Valdar W, Herrera BM, Criscuoli M, Yee IM, Sadovnick AD, Ebers GC; Canadian Collaborative Study Group: Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 2007; 6: 604–610.
22.
Edwards LJ, Constantinescu CS: A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler J 2004; 10: 575–581.
23.
Henderson RD, Bain CJ, Pender MP: The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci 2000; 7: 434–437.
24.
Midgard R, Grønning M, Riise T, Kvåle G, Nyland H: Multiple sclerosis and chronic inflammatory diseases. A case-control study. Acta Neurol Scand 1996; 93: 322–328.
25.
Nielsen NM, Frisch M, Rostgaard K, Wohlfahrt J, Hjalgrim H, Koch-Henriksen N, Melbye M, Westergaard T: Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler J 2008; 14: 823–829.
26.
Langer-Gould A, Albers KB, Van Den Eeden SK, Nelson LM: Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler J 2010; 16: 855–861.
27.
Roshanisefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery S: Shared genetic factors may not explain the raised risk of comorbid inflammatory diseases in multiple sclerosis. Mult Scler J 2012; 18: 1430–1436.
28.
O’Gorman C, Lucas R, Taylor B: Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. Int J Mol Sci 2012; 13: 11718–11752.
29.
Correale J, Farez MF, Gaitán MI: Environmental factors influencing multiple sclerosis in Latin America. Mult Scler J Exp Transl Clin 2017; 3: 2055217317715049.
30.
Olsson T, Barcellos LF, Alfredsson L: Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 2017; 13: 25–36.
31.
Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH: T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010; 162: 1–11.
32.
Hedegaard CJ, Krakauer M, Bendtzen K, Lund H, Sellebjerg F, Nielsen CH: T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 2008; 125: 161–169.
33.
Goverman J: Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009; 9: 393–407.
34.
Xu WD, Xie QB, Zhao Y, Liu Y: Association of Interleukin-23 receptor gene polymorphisms with susceptibility to Crohn’s disease: a meta-analysis. Sci Rep 2015; 5: 18584.
35.
Hamdy G, Darweesh H, Fawzy S, Khattab EA, Fawzy E, Sheta M: Association of interleukin-23 receptor (IL-23R) gene polymorphisms (rs11209026, rs2201841 and rs10889677) with Egyptian rheumatoid arthritis patients. Egypt Rheumatol 2015; 37: 159–163.
36.
Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I: Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011; 208: 2291–2303.
37.
Lozeron P, Denier C, Lacroix C, Adams D: Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009; 66: 490–497.
38.
Leray E, Moreau T, Fromont A, Edan G: Epidemiology of multiple sclerosis. Revue Neurol 2016; 172: 3–13.
39.
Phillips CJ: The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs 2004; 18: 561–574.
40.
Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F: Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991; 41: 692–696.
41.
Adelman G, Rane SG, Villa KF: The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ 2013; 16: 639–647.
42.
Brinar V, Barun B: Challenges in multiple sclerosis; how to define occurence of progression. Clin Neurol Neurosurg 2013; 115:S30–S34.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.